Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
203.75M | 219.49M | 168.87M | 147.47M | 147.54M | Gross Profit |
52.05M | 35.59M | 24.22M | 23.99M | 23.43M | EBIT |
18.28M | 3.63M | -2.61M | -1.32M | -2.35M | EBITDA |
18.04M | 8.16M | 916.00K | 459.00K | 281.00K | Net Income Common Stockholders |
18.75M | 1.36M | -6.00M | -3.61M | -4.62M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
23.27M | 8.08M | 4.43M | 5.21M | 4.37M | Total Assets |
134.77M | 118.90M | 118.77M | 89.38M | 83.93M | Total Debt |
11.00M | 12.92M | 9.44M | 16.15M | 13.80M | Net Debt |
-12.27M | 4.84M | 5.01M | 10.94M | 9.44M | Total Liabilities |
78.56M | 80.41M | 82.59M | 47.90M | 45.23M | Stockholders Equity |
54.76M | 37.41M | 35.69M | 41.24M | 38.41M |
Cash Flow | Free Cash Flow | |||
15.19M | -7.94M | -9.79M | -1.49M | 1.70M | Operating Cash Flow |
19.56M | -3.79M | -7.88M | 912.00K | 4.16M | Investing Cash Flow |
-4.37M | -4.15M | -1.91M | -2.40M | -2.46M | Financing Cash Flow |
-3.01M | 14.93M | 11.03M | 1.98M | -7.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $748.91M | 12.34 | 12.86% | 5.37% | -11.10% | -23.77% | |
72 Outperform | $1.71B | 14.16 | 12.40% | 2.10% | 1.81% | 8.09% | |
61 Neutral | $89.92M | 5.33 | 33.52% | ― | 9.44% | 102.67% | |
61 Neutral | $6.66B | 11.71 | 2.96% | 4.01% | 2.64% | -20.91% | |
56 Neutral | $162.42M | ― | -3.83% | 4.43% | -11.78% | -13.89% | |
48 Neutral | $90.93M | ― | -5.89% | 9.92% | -8.26% | -233.72% | |
47 Neutral | $161.57M | ― | 9.10% | ― | -12.36% | 37.69% |
Kewaunee Scientific Corporation has acquired Nu Aire, Inc. for $55 million, expanding its capabilities in the laboratory and technical product market. This acquisition allows Kewaunee to integrate Nu Aire’s well-regarded product line, which includes biological safety cabinets and CO2 incubators, into its offerings. The deal, financed partially through a loan from PNC Bank, enhances Kewaunee’s market presence and provides new growth opportunities, especially in regions previously untapped by Kewaunee. This strategic move positions the company for continued growth in recession-resistant industries like healthcare and life sciences.